Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidectin-albendazole for Trichuris trichiura in children
NCT06188715Phase 3
Key facts
- Status
- Completed
- Start
- May 2024
- Primary completion
- Aug 2024
- Countries
- 1
- Modality
- Allosteric Modulators
- Drugs
- moxidectin
- Conditions
- trichuriasis
01
Overview
Phase 3, randomised, double-blind trial of moxidectin in trichuriasis (3 arms). Primary endpoint: Cure Rate Against T. Trichiura. Started May 2024; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Moxidectin + Albendazole
Moxidectin (4/8 mg) + Albendazole (400 mg)
Albendazole
Albendazole (400 mg) + Placebo Moxidectin
Placebo
Placebo Moxidectin + Placebo Albendazole
03
Who it enrols
School-aged children (6-12 years) with confirmed Trichuris trichiura infection (2/4 positive Kato-Katz slides), excluding those with major systemic illness, severe anemia, or recent anthelminthic use.
04
Endpoints
Primary
Cure Rate Against T. Trichiura
Secondary
Egg Reduction Rate Against T. Trichiura
Cure Rate Against A. Lumbricoides
Egg Reduction Rate Against A. Lumbricoides
Cure Rate Against Hookworm
Egg Reduction Rate Against Hookworm
Number of Participants Reporting Adverse Events
Beyond the preview
Go deeper on NCT06188715.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188715.